Abstract

BackgroundOvarian germ cell tumours constitute a heterogeneous group of neoplasm with malignant potential being seen in 5% of cases. There is limited data on treatment outcomes of patients with malignant ovarian germ cell tumours (MOGCT). Here, we present our hospital audit of patients with MOGCT.Material and methodsThis is a retrospective data review of patients with MOGCT treated between May 2011 and December 2019. Patients were treated with staging laparotomy and adjuvant chemotherapy, wherever applicable. Surveillance was allowed for those at low risk for recurrence. Clinicopathologic features and treatment details were recorded, and survival analysis was performed.ResultsSixty-five patients with a median age of 25 years (range: 11–52 years) were treated during the study period. The most common histology was immature teratoma in 35.3% of cases. International Federation of Gynecology and Obstetrics stage IC was the most common stage of presentation (47%). Surveillance was advised for 12.3% of cases. Systemic therapy was given in 51 (78%) patients. At a median follow-up of 46 months (range: 1–109 months), the median progression-free survival (PFS) was not reached. Five-year PFS was 79.3% (95% CI: 65.8–88). The most common toxicity was febrile neutropenia (22%) among those who received systemic therapy.ConclusionImmature teratoma was the most common histology in our series. The majority presented in the early stage. MOGCT is a highly curable disease with surgery and systemic therapy.

Highlights

  • Malignant ovarian germ cell tumours (MOGCT) comprise less than 5% of all ovarian malignancies in the western countries

  • The fertility preservation approach at the time of surgery and avoidance of toxicity with systemic chemotherapy play a crucial role in the treatment of malignant ovarian germ cell tumours (MOGCT) [2]

  • Those who received at least one cycle of systemic chemotherapy or those who were kept under surveillance and had more than one outpatient follow-up visit with serum tumour markers were included for the survival analysis

Read more

Summary

Introduction

Malignant ovarian germ cell tumours (MOGCT) comprise less than 5% of all ovarian malignancies in the western countries. Because of the rarity of these tumours, there is limited published literature regarding the clinical profile and outcome of MOGCT. We report the clinicopathologic profile, treatment and outcome along with the treatment-related toxicity in patients with MOGCT from our institute. Ovarian germ cell tumours constitute a heterogeneous group of neoplasm with malignant potential being seen in 5% of cases. There is limited data on treatment outcomes of patients with malignant ovarian germ cell tumours (MOGCT). We present our hospital audit of patients with MOGCT

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call